Journal of Clinical Oncology
Articles in this Issue
Trends and disparities in hepatocellular carcinoma vs intrahepatic cholangiocarcinoma–related mortality in adults aged ≥ 45 years in the United States (1999-2024): A comparative CDC WONDER analysis.
e16489 Background: Hepatocellular Carcinoma (HCC) and Intrahepatic Cholangiocarcinoma (ICC) are the two most common types...
Clinical characteristics and survival outcomes of early-onset renal cell carcinoma by metastatic status: A National Cancer Database study.
e16510 Background: Early-onset RCC may reflect distinct biology and hereditary predisposition, yet data on stage-specific...
Early discontinuation of <sup>177</sup> Lu-PSMA-617 after ≤ 3 doses in prostate cancer: A single-center retrospective cohort study.
e17074 Background: 177 Lu-PSMA-617 is an FDA-approved radioligand therapy for prostate cancer. In clin...
Molecular characterization of ABL kinase domain mutations associated with imatinib resistance in chronic myeloid leukemia patients, including a novel pathogenic D276V variant.
e18598 Background: Imatinib resistance in chronic myeloid leukemia (CML) is frequently driven by BCR-ABL–dependent mechani...
Individualized recurrence risk prediction as a challenge to conventional eligibility criteria in phase III adjuvant immunotherapy trials for renal cell carcinoma.
e16501 Background: Adjuvant immunotherapy is recommended for high-risk patients with renal cell carcinoma (RCC) following...
Can transcriptome-based risk modeling improve survival stratification across cytogenetic groups in acute myeloid leukemia?
6533 Background: Cytogenetic risk stratification is central to prognostication in acute myeloid leukemia (AML), yet surviv...
Efficacy of immune therapy–based regimens in sarcomatoid lung cancer: A systematic review and meta-analysis.
e20769 Background: Sarcomatoid lung cancer/Pulmonary Sarcomatoid Carcinoma (PSC) is a rare, poorly differentiated, chemore...
Real-world use of regorafenib for refractory metastatic colorectal cancer: Survival outcomes and associated clinical features.
e15627 Background: Treatment options for refractory metastatic colorectal cancer (mCRC) remain limited. Regorafenib is com...
Anti–PD-1 (PD-1) monotherapy versus combination with anti–CTLA-4 for metastatic uveal melanoma (MUM) patients (pts).
9535 Background: MUM carries a poor prognosis with few effective treatments, especially for HLA-A*02:01-negative pts. Whil...
Baseline spatial tumor microenvironment states to define response and primary resistance to immune checkpoint inhibition in recurrent/metastatic head and neck squamous cell carcinoma.
6068 Background: Despite the clinical impact of immune checkpoint inhibitors (ICIs) in recurrent/metastatic head and neck...
Evaluation of the antitumor effect of 2-(1,1-Dimethyl-1h-benzo[E]indol-2-Yl)-5,6,7-trichloro-1,3-tropolone in in vivo models in monotherapy mode.
e14058 Background: This study evaluated the in vivo efficacy and safety of JO-122(...
Unmet rehabilitation needs in cancer survivors: A population-level analysis.
1584 Background: Decades of evidence demonstrate that patients across the cancer continuum may benefit from validated reha...
A phase II trial of fruquintinib combined with cadonilimab in refractory MSS/pMMR colorectal cancer with pulmonary metastases.
3552 Background: Immunotherapy for metastatic colorectal cancer (mCRC) with microsatellite stable/proficient mismatch repa...
Multicenter open-label randomized trial of the utility of electronic patient-reported outcome monitoring system in patients with advanced solid tumors (PRO-MOTE).
11004 Background: Randomized trials have suggested that electronic patient-reported outcome (ePRO) monitoring during syste...
Neoadjuvant serplulimab combined with cisplatin plus 5-fluorouracil in locally advanced head and neck squamous cell carcinoma: A phase II single-arm trial.
e18063 Background: Head and neck squamous cell carcinoma (HNSCC) remains a formidable clinical challenge, characterized by...
Multi-cohort validation of a multi-analyte liquid biopsy test for early-stage pancreatic cancer detection.
4139 Background: Pancreatic ductal adenocarcinoma (PDAC) has a 5-year survival rate below 12%, largely due to diagnosis at...
Phase II study of nab-paclitaxel and S-1 combined with tislelizumab as first-line treatment for advanced gallbladder cancer: Preliminary results.
e14575 Background: Chemotherapy combined with immunotherapy has become the standard treatment for advanced biliary tract a...
SOCCER: A randomized phase II trial comparing complete clinical response after short course radiation or chemoradiation and consolidation chemotherapy in rectal cancer.
3618 Background: The preferred total neoadjuvant treatment (TNT) regimen for an intentional watch-and-wait (W&W) appro...
Homologous recombination repair (HRR) genes and overall survival prognosis within the STRATOS-P classification in metastatic hormone-sensitive prostate cancer (mHSPC).
5108 Background: DNA repair genomic alterations are associated with worse overall survival (OS) in patients with metastati...
Type 2 cytokines in breast epithelial homeostasis.
e12588 Background: The widespread use of type 2 cytokine blockades (e.g., Dupilumab) has transformed treatment of inflamma...
Association of STK11 alterations with overall survival after immune checkpoint inhibitor therapy in TMB-low tumors: MSK-IMPACT cohort analysis.
e14551 Background: Tumor mutational burden (TMB) is associated with immune checkpoint inhibitor (ICI) outcomes, yet benefi...
The ASPIRES study: Promoting colorectal cancer surveillance in childhood cancer survivors—A randomized intervention trial from the Childhood Cancer Survivor study (CCSS).
10004 Background: Survivors of childhood cancer exposed to abdominal, pelvic, spinal, or total-body radiotherapy (RT) are...
Molecularly defined subgroups within RAS-WT mCRC: Treatment selection and overall survival in Project GENIE BPC CRC Database.
e15626 Background: RAS wild-type (WT) metastatic colorectal cancer (mCRC) remains clinically heterogeneous despite shared...
Association between chemotherapy-induced neuropathy and gabapentin exposure among adults receiving chemotherapy: A National Inpatient Sample study (2017-2021).
e24085 Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a common adverse effect of neurotoxic chemotherapy...
Real-world evidence of response to <sup>177</sup> Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) based on primary and metastatic sites in patients (pts) with neuroendocrine tumor (NET).
e16317 Background: NETs are rare tumors commonly originate from the gastrointestinal (GI) tract, pancreas, lung, and other...